Recent Acquisition Cerus Endovascular was acquired by Stryker in May 2023, indicating strong industry validation and potential increased market reach, making it a strategic partner or competitor within the neurovascular device segment.

Product Innovation The company specializes in next-generation highly differentiated neurointerventional devices for intracranial aneurysms, offering advanced minimally invasive solutions that could appeal to hospitals seeking cutting-edge treatment options.

Regulatory Progress With FDA 510(k) clearance achieved for its 027 microcatheters in March 2022, Cerus demonstrates a solid regulatory track record, facilitating accelerated sales efforts in the U.S. market for intracellular neurovascular devices.

Funding & Growth Having secured $19 million in Series B financing and maintaining modest revenue of under $1 million, Cerus presents opportunities for partners to support its growth trajectory through sales expansion or strategic collaborations.

Market Positioning As a privately held company with a focused product portfolio in neurointerventional devices and a dedicated medical device development team, Cerus is well-positioned to engage in targeted outreach to specialized neurovascular clinics and hospitals.